These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 1515280)
1. A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas. Aoki K; Shimada Y; Okazaki N; Tajiri H; Nose H; Okada S; Shirao K; Yokota T; Yoshida S; Saitoh D Eur J Cancer; 1992; 28A(8-9):1590. PubMed ID: 1515280 [No Abstract] [Full Text] [Related]
2. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Wils J; Bleiberg H; Blijham G; Dalesio O; Duez N; Lacave A; Splinter T Eur J Cancer Clin Oncol; 1985 Feb; 21(2):191-4. PubMed ID: 3857181 [TBL] [Abstract][Full Text] [Related]
3. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group. Wils J; Bleiberg H; Buyse M; Wagener DT; Splinter T; Veenhof C; Herben M; Duez N Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1119-20. PubMed ID: 2759166 [No Abstract] [Full Text] [Related]
4. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Topham C; Glees J; Coombes RC Oncology; 1993 Apr; 50 Suppl 1():78-80. PubMed ID: 8483561 [TBL] [Abstract][Full Text] [Related]
5. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Abad A; Massuti B; Blanco E; Carrato A; Maurel J; Cervantes A; Aranda E; Antón A; Vicent JM; Dorta J; Garcia de Paredes ML; Ariza A Am J Clin Oncol; 1998 Apr; 21(2):151-4. PubMed ID: 9537202 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409 [TBL] [Abstract][Full Text] [Related]
7. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO). Calero F; Asins-Codoñer E; Jimeno J; Rodriguez Escudero F; Mendaña J; Iglesias J; Matía F; Armas A; Díaz-Castellanos R; Garzón J Eur J Cancer; 1991; 27(7):864-6. PubMed ID: 1834118 [TBL] [Abstract][Full Text] [Related]
8. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group. Abad A; Masuti B; Camps C; Font A; Balañá C; Vicent JM; Sánchez JJ Eur J Cancer; 1994; 30A(7):1043. PubMed ID: 7946573 [No Abstract] [Full Text] [Related]
9. Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. Di Bartolomeo M; Zampino MG; Di Leo A; Bajetta E Eur J Cancer; 1993; 29A(8):1215-6. PubMed ID: 8518036 [No Abstract] [Full Text] [Related]
10. Phase II evaluation of melphalan in adenocarcinoma of the pancreas. Smith DB; Kenny JB; Scarffe JH; Maley WV Cancer Treat Rep; 1985; 69(7-8):917-8. PubMed ID: 4016799 [No Abstract] [Full Text] [Related]
11. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Crowson MC; Dorrell A; Rolfe EB; Fielding JW Eur J Surg Oncol; 1986 Dec; 12(4):335-6. PubMed ID: 3780986 [TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma. Sternberg CN; Magill GB; Sordillo PP; Cheng EW; Kemeny N Cancer Treat Rep; 1984; 68(7-8):1053-4. PubMed ID: 6744341 [No Abstract] [Full Text] [Related]
13. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Topham C; Glees J; Rawson NS; Woods EM; Coombes RC Br J Cancer; 1991 Jul; 64(1):179-81. PubMed ID: 1906726 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study. Kraut EH; Fleming T; Segal M; Neidhart JA; Behrens BC; MacDonald J Invest New Drugs; 1991 Feb; 9(1):95-6. PubMed ID: 1709154 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289 [TBL] [Abstract][Full Text] [Related]
16. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma. Maiello E; Gebbia V; Giuliani F; Testa A; Giotta F; Gebbia N; Colucci G Clin Ter; 1998; 149(5):351-5. PubMed ID: 10052247 [TBL] [Abstract][Full Text] [Related]
17. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. Mambrini A; Sanguinetti F; Pacetti P; Caudana R; Iacono C; Guglielmi A; Guadagni S; Del Freo A; Fiorentini G; Cantore M In Vivo; 2006; 20(6A):751-5. PubMed ID: 17203761 [TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of mitoguazone in cancers of the esophagus, stomach, and pancreas: a Southeastern Cancer Study Group Trial. Ravry MJ; Omura GA; Hill GJ; Bartolucci AA; Velez-Garcia E Cancer Treat Rep; 1986 Apr; 70(4):533-4. PubMed ID: 3698050 [No Abstract] [Full Text] [Related]
19. Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma. Moertel CG; Douglass HO; Hanley J; Carbone PP Cancer Treat Rep; 1976 Nov; 60(11):1659-61. PubMed ID: 1035508 [No Abstract] [Full Text] [Related]
20. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. DeCaprio JA; Mayer RJ; Gonin R; Arbuck SG J Clin Oncol; 1991 Dec; 9(12):2128-33. PubMed ID: 1960554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]